Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtains drug registration certificate for Sacubitril Valsartan Sodium Tablets.
Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Shandong Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Related Articles
WEIGAO GROUP (01066) repurchased 140,000 shares for HK$461,400 on September 23.
UBS Group AG (UBS.US) Capital Rules Hit Setback in Parliamentary Approval as Swiss Upper House Passes Plan Requiring 90% CET1 Support from Overseas Subsidiaries
ZYLOXTB (02190) repurchased 54,500 shares for HK$1.1487 million on September 23.
WEIGAO GROUP (01066) repurchased 140,000 shares for HK$461,400 on September 23.
UBS Group AG (UBS.US) Capital Rules Hit Setback in Parliamentary Approval as Swiss Upper House Passes Plan Requiring 90% CET1 Support from Overseas Subsidiaries
ZYLOXTB (02190) repurchased 54,500 shares for HK$1.1487 million on September 23.
